ClinicalTrials.gg
CompletedNCT04729751RISEUpdated Jun 2, 2026Results posted

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

A Phase 2 interventional study of Maralixibat in Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome and Cholestatic Liver Disease, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 14 sites in 7 countries. Open to participants aged 0 Days to 364 Days. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
0 Days to 364 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Cholestasis, progressive familial intrahepatic 1 · United States.

Started
2021
the only one that year
Phase 2
2 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
6 of 10
Mirum Pharmaceuticals, Inc.

Among the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, this one is the only one that started in 2021, is one of 2 in phase 2, and was the 9th registered.

Cholestasis, progressive familial intrahepatic 1

33 studies on the registry are indexed under Cholestasis, progressive familial intrahepatic 1; 13 are open to participants now.

Browse Cholestasis, progressive familial intrahepatic 1 studies →

Open to participants now

1 of the 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Cholestasis, progressive familial intrahepatic 1 studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 0 Days to 364 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cholestasis, progressive familial intrahepatic 1 with a site in United States, or all of them as a file.
02

Study summary

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children \<12 months of age with Alagille Syndrome [ALGS] or Progressive Familial Intrahepatic Cholestasis [PFIC].

Read the detailed description

This is an open label study where all participants will receive maralixibat treatment.

03

Conditions studied

  • Progressive Familial Intrahepatic Cholestasis
  • Alagille Syndrome
  • Cholestatic Liver Disease

Keywords

  • PFIC
  • ALGS
  • Maralixibat
  • Bile Duct Diseases
  • Liver Diseases
  • Biliary Tract Diseases
  • Pediatric
04

Who can participate

Ages eligible
0 Days to 364 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Body weight of ≥2.5 kg
  2. \<12 months of age at the baseline visit (ROW). >31 days and \<12 months of age at the baseline visit (US).
  3. Gestational age ≥36 weeks at birth. For children born with gestational age between 32 and 36 weeks, a postmenstrual age of ≥36 weeks is required.
  4. Diagnosis of PFIC or ALGS

Exclusion criteria

Exclusion criteria:

  1. Predicted complete absence of bile salt excretion pump (BSEP) function
  2. History of surgical disruption of the enterohepatic circulation
  3. History of liver transplant or imminent need for liver transplant
  4. Decompensated cirrhosis
  5. Presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (e.g., inflammatory bowel disease), per investigator discretion
  6. Presence of other significant liver disease or any other conditions or abnormalities which, in the opinion of the investigator or medical monitor, may compromise the safety of the participant or interfere with the participant's participation in or completion of the study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Maralixibat

    Participants will receive up to 600 μg/kg twice daily (PFIC) or up to 400 μg/kg once daily (ALGS) over 13 weeks in the core study and for the duration of the Long Term Extension (LTE) where applicable.

    Drug: Maralixibat

Interventions

  • Maralixibat chloride provided in the form of an oral solution (i.e., 5, 10, 15, and 20 mg/mL) * 400 μg/kg maralixibat chloride is equivalent to 380 µg/kg maralixibat free base * 600 μg/kg maralixibat chloride is equivalent to 570 µg/kg maralixibat free base

    Also known as: Formerly LUM001 and SHP625

06

What researchers measure

Primary outcomes

  1. Frequency of Treatment-emergent Adverse Events [TEAEs]

    TEAEs = Treatment-emergent Adverse Events

    Time frame: From Baseline through to Week 13

Secondary outcomes

  1. Change in Fasting Serum Bile Acid (sBA) Levels

    sBA = serum bile acid

    Time frame: From Baseline through to Week 13

  2. To Evaluate the Effect on Liver Enzymes (ALT)

    ALT= alanine aminotransferase.

    Time frame: From Baseline through to Week 13

  3. Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin E

    Change from baseline to Week 13 in vitamin E.

    Time frame: From Baseline through to Week 13

  4. Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for ALGS

    BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 400 μg/kg QD for ALGS or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 400 µg/kg QD.

    Time frame: At Baseline, Week 6, Week 10, Week 13 or Early Termination Visit

  5. To Evaluate the Effect on Liver Enzymes (AST)

    AST= aspartate aminotransferase

    Time frame: From Baseline through to Week 13.

  6. To Evaluate the Effect on Bilirubin

    Bilirubin

    Time frame: From Baseline through to Week 13

  7. Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin A

    Change from baseline to Week 13 in vitamin A

    Time frame: From Baseline through to Week 13

  8. Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamins D and K

    Change from baseline to Week 13 in vitamins D and K.

    Time frame: From Baseline through to Week 13

  9. Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for PFIC

    BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 300 μg/kg QD, 300 μg/kg BID and 600 μg/kg BID for PFIC or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 600 µg/kg BID.

    Time frame: At Baseline, Week 6, Week 10, Week 13 or Early Termination Visit

07

Results

Posted Jun 2, 2026

Participant flow

A total of 27 participants were enrolled in the study, across 10 sites in 6 countries (Belgium, Brazil, France, Poland, United Kingdom, and United States), 17 patients in the ALGS Cohort and 10 in the PFIC Cohort.

Participant flow — Overall Study
MilestoneMaralixibat: ALGSMaralixibat: PFIC
Started1710
Completed169
Not completed11
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01

Outcome measures

PrimaryFrequency of Treatment-emergent Adverse Events [TEAEs]

TEAEs = Treatment-emergent Adverse Events

Time frame:
From Baseline through to Week 13
Reported as:
Count of participants · Participants
Frequency of Treatment-emergent Adverse Events [TEAEs]
ParticipantsMaralixibat: ALGSMaralixibat: PFIC
At least one TEAE1610
TEAE related to study drug43
Grade ≥3 TEAE61
Grade ≥3 TEAE related to study drug00
Serious TEAE62
Serious TEAE related to study drug00
TEAE that led to study discontinuation01
TEAE that led to death00
SecondaryChange in Fasting Serum Bile Acid (sBA) Levels

sBA = serum bile acid

Time frame:
From Baseline through to Week 13
Reported as:
Mean · µmol/L
Change in Fasting Serum Bile Acid (sBA) Levels
µmol/LMaralixibat: ALGSMaralixibat: PFIC
Baseline292.81 ± 218.756228.32 ± 107.52
Week 13172.49 ± 109.924138.90 ± 91.610
Change from Baseline-75.68 ± 115.669-77.49 ± 128.616
SecondaryTo Evaluate the Effect on Liver Enzymes (ALT)

ALT= alanine aminotransferase.

Time frame:
From Baseline through to Week 13
Reported as:
Mean · U/L
To Evaluate the Effect on Liver Enzymes (ALT)
U/LMaralixibat: ALGSMaralixibat: PFIC
ALT, U/L Baseline167.35 ± 106.018149.00 ± 110.108
ALT, U/L Week 13256.87 ± 190.73280.50 ± 41.946
ALT, U/L Change from Baseline99.00 ± 190.981-27.00 ± 25.031
SecondaryChange From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin E

Change from baseline to Week 13 in vitamin E.

Time frame:
From Baseline through to Week 13
Reported as:
Mean · mg/L
Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin E
mg/LMaralixibat: ALGSMaralixibat: PFIC
Vitamin E mg/L Baseline6.54 ± 5.3512.78 ± 2.149
Vitamin E mg/L Week 135.99 ± 5.0843.98 ± 3.658
Vitamin E mg/L Change from Baseline-0.46 ± 2.2140.92 ± 1.422
SecondaryMaximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for ALGS

BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 400 μg/kg QD for ALGS or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 400 µg/kg QD.

Time frame:
At Baseline, Week 6, Week 10, Week 13 or Early Termination Visit
Reported as:
Mean · ng/mL
Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for ALGS
ng/mLMaralixibat: ALGS
Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for ALGS0.5576 ± 0.6107
SecondaryTo Evaluate the Effect on Liver Enzymes (AST)

AST= aspartate aminotransferase

Time frame:
From Baseline through to Week 13.
Reported as:
Mean · U/L
To Evaluate the Effect on Liver Enzymes (AST)
U/LMaralixibat: ALGSMaralixibat: PFIC
AST, U/L Baseline184.12 ± 105.42159.10 ± 97.034
AST, U/L Week 13236.8 ± 142.54085.71 ± 36.068
AST, U/L Change from Baseline69.27 ± 136.827-30.43 ± 32.264
SecondaryTo Evaluate the Effect on Bilirubin

Bilirubin

Time frame:
From Baseline through to Week 13
Reported as:
Mean · µmol/L
To Evaluate the Effect on Bilirubin
µmol/LMaralixibat: ALGSMaralixibat: PFIC
Total bilirubin, µmol/L Baseline142.54 ± 102.32341.02 ± 23.651
Total bilirubin, µmol/L Week 13114.89 ± 102.78918.51 ± 16.720
Total bilirubin, µmol/L Change from Baseline-22.85 ± 46.252-18.01 ± 18.781
SecondaryChange From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin A

Change from baseline to Week 13 in vitamin A

Time frame:
From Baseline through to Week 13
Reported as:
Mean · umol/L
Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamin A
umol/LMaralixibat: ALGSMaralixibat: PFIC
Vitamin A umol/L Baseline1.78 ± 1.1891.50 ± 0.991
Vitamin A umol/L Week 132.08 ± 1.0312.32 ± 0.884
Vitamin A umol/L Change from Baseline0.45 ± 0.6780.61 ± 0.878
SecondaryChange From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamins D and K

Change from baseline to Week 13 in vitamins D and K.

Time frame:
From Baseline through to Week 13
Reported as:
Mean · nmol/L
Change From Baseline to Week 13 in Lipid-Soluble Vitamins (LSVs) - Vitamins D and K
nmol/LMaralixibat: ALGSMaralixibat: PFIC
Vitamin D nmol/L Baseline62.64 ± 58.56362.87 ± 60.308
Vitamin D nmol/L Week 1378.42 ± 58.95294.84 ± 56.849
Vitamin D nmol/L Change from Baseline7.63 ± 79.38320.65 ± 44.394
Vitamin K nmol/L Baseline31.22 ± 84.3150.21 ± 0.133
Vitamin K nmol/L Week 1314.64 ± NA—
Vitamin K nmol/L Change from Baseline-241.14 ± NA—
SecondaryMaximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for PFIC

BID=twice daily; QD=once daily. Systemic concentrations of maralixibat in plasma were determined at the following visits: * Approximately 2.5 hours after the morning dose at Week 0/Day 1 of dosing * Before dosing and \~2.5 hours after the morning dose at Week 6, Week 10, and Week 13 Stable dosing occurred at 300 μg/kg QD, 300 μg/kg BID and 600 μg/kg BID for PFIC or at the highest tolerated dose. Note: The values added in section Measured Values are for maralixibat dose of 600 µg/kg BID.

Time frame:
At Baseline, Week 6, Week 10, Week 13 or Early Termination Visit
Reported as:
Mean · ng/mL
Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for PFIC
ng/mLMaralixibat: PFIC
Maximum Level of Maralixibat Concentration in Plasma From Baseline to Week 13 for PFIC0.153 ± 0.2629

Adverse events

Collected over The timeframe for reporting adverse events was from Baseline to study week 147.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maralixibat: ALGS0/17 (0%)6/17 (35.3%)16/17 (94.1%)
Maralixibat: PFIC0/10 (0%)2/10 (20%)10/10 (100%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventMaralixibat: ALGSMaralixibat: PFIC
Intestinal obstructionGastrointestinal disorders0/171/10
Abdominal sepsisInfections and infestations0/171/10
Adenovirus infectionInfections and infestations0/171/10
Appendicitis perforatedInfections and infestations0/171/10
Gastroenteritis adenovirusInfections and infestations0/171/10
InfluenzaInfections and infestations0/171/10
CryingGeneral disorders1/170/10
PyrexiaGeneral disorders1/170/10
DiarrhoeaGastrointestinal disorders1/170/10
Infantile colicGeneral disorders1/170/10
Most frequent other events
Showing 10 of 25
Most frequent other events
EventMaralixibat: ALGSMaralixibat: PFIC
VomitingGastrointestinal disorders2/175/10
DiarrhoeaGastrointestinal disorders7/174/10
NasopharyngitisInfections and infestations6/174/10
Upper respiratory tract infectionInfections and infestations4/174/10
Viral infectionInfections and infestations4/174/10
InvestigationsInvestigations3/173/10
CoagulopathyBlood and lymphatic system disorders0/173/10
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/173/10
CoughRespiratory, thoracic and mediastinal disorders4/172/10
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders4/172/10

Baseline characteristics

Age, Customized
Age, Customized(Participants)Maralixibat :ALGSMaralixibat: PFICTotal
Preterm newborn - gestational age < 37 weeks000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)171027
Sex: Female, Male
Sex: Female, Male(Participants)Maralixibat :ALGSMaralixibat: PFICTotal
Female336
Male14721
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Maralixibat :ALGSMaralixibat: PFICTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White7613
More than one race101
Unknown or Not Reported9413
Region of Enrollment
Region of Enrollment(participants)Maralixibat :ALGSMaralixibat: PFICTotal
Belgium101
United States617
Poland437
Brazil404
United Kingdom235
France213
08

Study locations

14 sites
  • Children Hospital LA
    Los Angeles, California 90027, United States
  • University of California - San Francisco
    San Francisco, California 94158, United States
  • Medstar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • Ochsner Hospital for Children
    New Orleans, Louisiana 70121, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Cliniques Universitaires Saint-Luc
    Brussels, Belgium
  • Sociedade Beneficente de Senhoras - Hospital Sírio-Libanês
    São Paulo, 01308-000, Brazil
  • Hôpital Kremlin Bicêtre
    Le Kremlin-Bicêtre, France
  • Hopital Necker
    Paris, France
  • Consultorio de Joshue David Covarrubias Esquer
    Zapopan, 45050, Mexico
  • Instytut Pomnik-Centrum Zdrowia Dziecka
    Warsaw, Poland
  • King's College Hospital
    London, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Dec 2024, 39 months.

Results were first posted in Jun 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 28, 2021
StartActual
Sep 9, 2021
Primary completionActual
Dec 17, 2024
CompletionActual
Dec 17, 2024
Results first posted
Jun 2, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04729751
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Sep 9, 2021
Primary completion
Dec 17, 2024
Completion
Dec 17, 2024
Results posted
Jun 2, 2026
Last update
Jun 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion